VACCINEX, INC.|4Apr 2, 4:26 PM ET

Leonard John E. 4

4 · VACCINEX, INC. · Filed Apr 2, 2021

Form 4

Period: 2021-04-02

SVP, Development

Transactions

Award
Stock Option (Right to Buy)
2021-04-02+8,000→ 8,000 total
Exercise: $2.93Exp: 2031-04-02→ Common Stock (8,000 underlying)

Holdings

Common Stock
2,258
Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-22→ Common Stock (1,258 underlying)
23,150
Stock Option (Right to Buy)
Exercise: $3.90Exp: 2029-03-14→ Common Stock (1,000 underlying)
3,000
Common Stock
(indirect: By LLC)
1,014
Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-23→ Common Stock (3,062 underlying)
3,062
Stock Option (Right to Buy)
Exercise: $6.07Exp: 2030-02-24→ Common Stock (4,000 underlying)
4,000

Footnotes (4)

[F1]Exercisable in full as of the date of this report.
[F2]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
[F3]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
[F4]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.

Documents

1 file